CPRX Q2 2021 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+22.8% YoY

Gross Profit

$32M87.5% margin

Operating Income

$16M43.6% margin

Net Income

$12M33.5% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+20.4%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$209M

Total Liabilities

$20M

Stockholders' Equity

$189M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$30M	+22.8%
Gross Profit	$32M	$25M	+25.0%
Operating Income	$16M	$10M	+54.0%
Net Income	$12M	$10M	+24.6%

Revenue Segments

Product Revenue, Net

$34M100%